- Report
- July 2024
- 138 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- April 2025
- 273 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- May 2024
- 184 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- January 2022
- 121 Pages
Global
From €4323EUR$4,750USD£3,706GBP
Anorexiants are a class of drugs used to treat obesity and related conditions. They are classified as central nervous system (CNS) drugs, meaning they act on the brain and nervous system to reduce appetite and increase feelings of fullness. Anorexiants are typically prescribed to people who are overweight or obese and have not been able to lose weight through diet and exercise alone. Common side effects of anorexiants include dry mouth, constipation, and insomnia.
The anorexiant market is a growing segment of the CNS drug market. It is driven by the increasing prevalence of obesity and the need for effective treatments. Anorexiants are typically prescribed in combination with lifestyle changes such as diet and exercise, and are often used as a last resort when other treatments have failed.
Some companies in the anorexiant market include Arena Pharmaceuticals, Orexigen Therapeutics, Vivus, and Eisai. Show Less Read more